THE ROLE OF MYELOPEROXIDASE AS AN EARLY PREDICTOROF CARDIOTOXICITY

Abstract

Myeloperoxidase (MPO) is considered a potential biomarker for early detection of cardiotoxicity in patients undergoing anticancer treatment. However, data regarding its prognostic value remain limited and inconsistent. Aim: To assess the role of MPO as an early predictor for the development of cardiotoxicity and mortality. Methods: A total of 477 patients receiving antineoplastic therapy were followed, with measurements of MPO, troponin, NT-proBNP, and comprehensive echocardiographic evaluation performed at baseline, 3 months, and 6 months. We evaluated and compared the association between these biomarkers and the development of a > 10% decline in left ventricular ejection fraction (EF) to values < 55%, a > 15% reduction in global longitudinal strain (GLS) from baseline, and mortality. Results: MPO showed no significant association with changes in LVEF (p-value = 0.42) or GLS (p-value = 0.578). However, higher MPO levels were associated with an increased risk of early mortality, independent of other clinical and imaging parameters (p-value = 0.0287). Conclusion: These findings highlight the potential of MPO to complement existing risk-stratification tools and indicate the need for further studies to clarify its mechanisms and clinical utility.